[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55: 2005-2023.
[2] Aubert J, Begriche K, Knockaert L, et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol, 2011, 35: 630-637.
[3] Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet, 2002, 360: 1155-1162.
[4] Chiba T, Noji K, Shinozaki S, et al. Diet-induced non-alcoholic fatty liver disease affects expression of major cytochrome P450 genes in a mouse model. J Pharm Pharmacol, 2016, 68: 1567-1576.
[5] Osabe MJ, Sugatani, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos, 2008, 36: 294-302.
[6] Abdelmegeed MA, Banerjee A, Yoo SH, et al. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol, 2012, 57: 860-866.
[7] Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver?. Curr Drug Metab, 2011, 12: 24-34.
[8] Luo ZL, Tang LJ, Wang T, et al. Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol, 2014, 29: 215-222.
[9] Deng QG, She H, Cheng JH, et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology, 2005, 42: 905-914.
[10] Pass GJ, Becker W, Kluge R, et al. Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population. J Pharmacol Exp Ther, 2002, 302: 442-450.
[11] Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos, 2009, 37: 2087-2094.
[12] Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond), 2004, 106: 261-268.
[13] Liu Y, Jin Y, Jiang PP, et al. Dynamic observation of CYP1A2 activity in nonalcoholic fatty liver disease process of rats by phenacetin probe method. China Pharmacy, 2012, 22: 1559-1561.
[14] Aljomah G, Baker SS, Liu W, et al. Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol, 2015, 99: 677-681.
[15] Engstler AJ, Aumiller T, Degen C, et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut, 2016, 65: 1564-1571.
[16] Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol, 2013, 58: 395-398.
[17] Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest, 2000, 105: 1067-1075.
[18] Jearapong N, Chatuphonprasert W, Jarukamjorn K. Effect of tetrahydrocurcumin on the profiles of drug-metabolizing enzymes induced by a high fat and high fructose diet in mice. Chem Biol Interact, 2015, 239: 67-75.
[19] Sakuma T, Honma R, Maguchi S, et al. Different expression of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic mouse and rat. Xenobiotica, 2001, 31: 223-237.
[20] Xie X, Miao L, Yao J, et al. Role of multiple microRNAs in the sexually dimorphic expression of Cyp2b9 in mouse liver. Drug Metab Dispos, 2013, 41: 1732-1737.
[21] Mota LC, Hernandez JP, Baldwin WS. Constitutive androstane receptor -null mice are sensitive to the toxic effects of parathion: association with reduced cytochrome p450-mediated parathion metabolism. Drug Metab Dispos, 2010, 38: 1582-1588.
[22] Hashita T, Sakuma T, Akada M, et al. Forkhead box A2-mediated regulation of female-predominant expression of the mouse Cyp2b9 gene. Drug Metab Dispos, 2008, 36: 1080-1087.
[23] Hoek-van den Hil EF, van Schothorst EM, van der Stelt I, et al. Direct comparison of metabolic health effects of the flavonoids quercetin, hesperetin, epicatechin, apigenin and anthocyanins in high-fat-diet-fed mice. Genes Nutr, 2015, 10: 469.
[24] Schuck RN, Zha W, Edin ML, et al. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One, 2014, 9: e110162.
[25] Wells MA, Vendrov KC, Edin ML, et al. Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. Prostaglandins Other Lipid Mediat, 2016, 125: 19-29.
[26] Chen G, Xu R, Zhang S, et al. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. Am J Physiol Endocrinol Metab, 2015, 308: E97-E110.
[27] Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 1999, 39: 1-17.
[28] Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos, 2015, 43: 1484-1490.
[29] Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov, 2016, 15: 249-274.
[30] Zhang X, Li S, Zhou Y, et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A, 2017, 114:3181-3185.
[31] Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol, 2008, 75: 2263-2275. |
